Varithena is owned by Provensis.
Varithena contains Polidocanol.
Varithena has a total of 5 drug patents out of which 1 drug patent has expired.
Expired drug patents of Varithena are:
Varithena was authorised for market use on 25 November, 2013.
Varithena is available in solution;intravenous dosage forms.
Varithena can be used as a method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct injection into varicosities, a method of generating an injectable foam of controlled density and bubble size.
The generics of Varithena are possible to be released after 12 May, 2032.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7731986 | PROVENSIS | Therapeutic foam |
Nov, 2024
(1 year, 9 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6846412 | PROVENSIS | Combination filter assembly |
Jul, 2022
(6 months ago) | |
US8122917 | PROVENSIS | Apparatus and method for dispensing foam |
Sep, 2024
(1 year, 7 months from now) | |
US7814943 | PROVENSIS | Apparatus and method for dispensing foam |
Nov, 2027
(4 years from now) | |
US9480652 | PROVENSIS | Aerosol valve |
May, 2032
(9 years from now) |
Drugs and Companies using POLIDOCANOL ingredient
Market Authorisation Date: 25 November, 2013
Treatment: A method of generating an injectable foam of controlled density and bubble size; A method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct injection into varicosities
Dosage: SOLUTION;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic